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Wood-Smoke Exposure
as a Response and
Survival Predictor in
Erlotinib-Treated
Nonsmall Cell Lung
Cancer Patients
To the Editor:
In relation to the letter to the edi-
tor written by Cardona et al.1 published
in the Journal of Thoracic Oncology on
January 2009 referring to our article
entitled “Wood-Smoke Exposure as a Re-
sponse and Survival Predictor in Erlotinib-
treated Nonsmall Cell Lung Cancer Pa-
tients: An Open Label Phase II Study,”2 in
which Cardona et al. concluded that the
findings that we previously published are
not supported by them, some statements
should be made: their study is based ex-
clusively on an experience-established
treatment of 156 adenocarcinoma patients,
not a prospective clinical trial. Of these
156 patients, only 23% (36 patients) re-
ceived erlotinib. It does not mention at-
tachment to treatment of the patients,
which might be an issue, considering
that those exposed to wood-smoke gen-
erally belong to lower socioeconomic
status than those who have no history
of exposure and depend on study in-
clusion to receive treatment.
Moreover, of the erlotinib-treated
patients, just nine of them had wood-
smoke exposure (WSE) history and seven
of them also had smoking history for an
average of 14 years. Our hypothesis about
nonsmall cell lung cancer patients with
WSE and their response to tyrosine kinase
inhibitors treatment suggests that the path-
ways involved in carcinogenesis in WSE
patients and smokers are different, reason
for which nonsmall cell lung cancer de-
velopment could be attributed solely to
WSE in two patients of their series. There-
fore, the sample is not representative.
Furthermore, there is a mistake in
their statistical analysis. Cardona et al.
states a 5% response rate to erlotinib in
WSE patients with a sample size of
merely nine patients, which corresponds
to 0.45 patients, assuming that only one
patient had shown response it would be
equal to 11.11% of patients.
Also, their reported response rate
in non-WSE patients, including smokers
and nonsmokers, is of 47%, which is
strikingly high and is different from data
that have been previously reported by
Shepherd et al.3 in a phase III study that
included 731 patients with a response
rate of 8.9% and, exclusively, 29% of
patients in the adenocarcinoma subtype.
Their rate of response is not comparable
either with the TRUST4 study that in-
vestigated the extended use of erlotinib
in 5448 patients with a reported response
rate of 12%. However, this information is
consistent with our finding of a response
rate of 12.3% in non-WSE patients. We
would welcome the authors’ clarification
of their numbers in case we have misin-
terpreted them.
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Esophageal Ultrasound-
Controlled Fine Needle
Aspiration for Staging
of Mediastinal Lymph
Nodes in Patients with
Resectable Lung
Cancer: Do We Always
See the Reality?
To the Editor:
Accurate mediastinal lymph node
staging is pivotal in the staging and
treatment of non-small cell lung can-
cer.1,2 Echoendoscopic needle aspira-
tion is a minimally invasive staging
technique with a good sensitivity and
100% specificity. However, physicians
performing and relying on esophageal
ultrasound-controlled fine needle aspi-
ration (EUS-FNA) should be aware of
potential hurdles related to this tech-
nique such as
Parenchymal lung lesions adjacent to
the esophagus can be sampled and
care must be taken in their radio-
graphic and cytologic interpretation.
Lymphocytes in an needle aspiration
sample do not always indicate a lymph
node was sampled.
EUS-FNA may allow sampling of hilar
lymph nodes.
As such, EUS-FNA may result in clini-
cal overstaging (N2 instead of N0 or N1)
having an important impact on patient
treatment and prognosis. Here, we
present two cases illustrating potential
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hurdles performing EUS-FNA for medi-
astinal staging.
A woman presented with a suspi-
cious lung mass in the posterior part of
the right lower lobe and a second mass
adjacent to the esophagus that was con-
sidered a second parenchymal mass (sharp
angles of the opacity) or a paraesopha-
geal mediastinal lymph node (sharp an-
gles because of lymph node volume)
(Figure 1). EUS showed a round, well-
defined hypoechogenic paraesophageal
lesion revealing on needle aspiration cy-
tology malignant cells embedded in lym-
phocytes. Therefore, the clinical stage
was considered cT2N2M0. A cervical
mediastinoscopy with nodal mapping
showed normal lymph nodes (posi-
tions 2/4R, 4L, 7). At thoracotomy, we
found a tumor in the right lower lobe
and a second subpleural intraparen-
chymal ovoid tumor in the same lobe
situated adjacent to the pleura at the
level of the esophagus. Thus, patho-
logic characteristics of the resection
specimen after right lower lobe lobec-
tomy with systemic nodal dissection de-
scribed two locations of solid pulmo-
nary adenocarcinoma, staged as pT4N0,
harboring lymphoid aggregates.3 Appar-
ently, EUS-FNA and its cytologic inter-
pretation suggested a mediastinal lymph
node for a lesion, finally proven to be
a parenchymal tumor.
Years ago, a man underwent che-
moradiotherapy for Hodgkin’s disease;
lung fibrosis due to bleomycin had oc-
curred. Now, he presented with non-
small cell lung cancer of the left lower
lobe and Fluoro Deoxy Glucose Position
Emission Tomography positive lymph
nodes in the left hilum (level 11L) and in
the paraesophageal level 8 (level 8L on
CT; Fig. 2). EUS-FNA of the para-
esophageal lymph node revealed malig-
nant cells embedded in lymphocytes.
The final clinical stage was considered
cT2N2M0. Because of his medical his-
tory, he was not able to undergo chemo-
radiotherapy; we considered him operable
after a negative cervical mediastinoscopy.
During thoracotomy, we found a tumor in
the left lower lobe with a malignant hilar
lymph node at the ostium of the left lower
lobe bronchus (level 10L). The final
pathologic findings of the resection spec-
imen was staged as pT2N1. Apparently,
EUS-FNA had identified a lymph node as
mediastinal, although it was finally proved
to be a hilar lymph node.
In conclusion, caution must al-
ways be taken in the interpretation of
the anatomy on imaging.4 Not only the
implementation of the International
Association for the Study of Lung
Cancer lymph node map on computed
tomography but also correct echoen-
doscopy interpretation is warranted to
improve the N stage classification.
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FIGURE 1. Case 1: a patient with a lung mass in the posterior part of the right
lower lobe (not shown) and a second mass adjacent to the esophagus (indicated
with an asterisk).
FIGURE 2. Case 2: a patient with squamous cell lung carcinoma of the left lower
lobe (not shown) and on CT scan a lymph node in the paraesophageal level (level
8L; indicated with an asterisk) and left hilum (level 11L).
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Clinicopathological Characteristics of Screen-Detected Lung Cancers: Erratum
In the article that appeared on page 615 of the May 2009 issue of the Journal of Thoracic Oncology, several errors have been identified. These
errors appeared in the Abstract as well as the text. The data should have matched below. The new data is in bold for emphasis only. These errors
have been noted in the online version of the article at www.jto.org.
ABSTRACT
Patients
Patients were classified into three groups according to the method of detection: SCR (n1279), symptom-detected (SYM, n466), and incidental
(INC, n536).
Results
The 5-year survival rates in SCR, SYM, and INC group were 79.6%, 64.6%, and 74.6%, respectively.
TEXT
Results
Survival According to the Method of Detection:
The 5-year survival rates in SCR, SYM, and INC group were 79.6%, 64.6%, and 74.6%, respectively.
Comment
SCR lung cancers were not only smaller (2cm or less in diameter: 42.6%) and at a lower stage (pathologic stage I: 70.8%), but also more
often adenocarcinoma (85.8%) than SYM lung cancers.
In particular, such findings were more evident with CT in the SCR group (2cm or less in diameter: 76.4%, pathologic stage I: 92.6%, and
adenocarcinoma: 92.6%).
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